Editorial: Alzheimer's Disease: Original Mechanisms and Translational Impact.

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive and irreversible worsening of cognitive functions, inability to perform everyday activities, and mood disorders. As recently reported by [5], 132 drugs are under clinical development for AD and only 28 of them are in phase III; among these latter, nine are anti-amyloid agents, eight are compounds targeting neuropsychiatric symptoms, and only three are antioxidant/neurotransmitter-based therapies. Over the last few years, many drugs, initially authorized and marketed for the treatment of other diseases, have proven to be potentially effective for the treatment of AD. Decoding the synaptic dysfunction of bioactive human AD brain soluble A to inspire novel therapeutic avenues for Alzheimer's disease. [Extracted from the article]